title: Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.
authors: Department of Hematology AZ St-Jan Brugge-Oostende, Belgium.
authors: Dominik
authors: D
authors: Selleslag
authors: EORTC Headquarters, Brussels, Belgium.
authors: Stefan
authors: S
authors: Suciu
authors: Hematology, Sapienza University, Rome, Italy.
authors: Giovanna
authors: G
authors: Meloni
authors: Department of Hematology, Radboud University, Medical Center, Nijmegen, the Netherlands.
authors: Petra
authors: P
authors: Muus
authors: Department of Hematology, Leiden University Medical Center, the Netherlands.
authors: Constantijn J M
authors: CJ
authors: Halkes
authors: Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
authors: Adriano
authors: A
authors: Venditti
authors: EORTC Headquarters, Brussels, Belgium.|Department of Hematology, Istituto Europeo di Oncologia, Milan, Italy.
authors: Safaa M
authors: SM
authors: Ramadan
authors: Jeroen Bosch Medical Center, Den Bosch, the Netherlands.
authors: Hans
authors: H
authors: Pruijt
authors: EORTC Headquarters, Brussels, Belgium.
authors: Liv
authors: L
authors: Meert
authors: Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA), Rome, Italy.
authors: Marco
authors: M
authors: Vignetti
authors: Department of Hematology, Hôpital Saint-Antoine, APHP, Paris, France.
authors: Jean-Pierre
authors: JP
authors: Marie
authors: Department of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium.
authors: Sébastian
authors: S
authors: Wittnebel
authors: Department of Tumorimmunology, Radboud University, Medical Center, Nijmegen, the Netherlands.
authors: Theo
authors: T
authors: de Witte
authors: Department of Hematology and of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
authors: Sergio
authors: S
authors: Amadori
authors: Department of Hematology, Leiden University Medical Center, the Netherlands.
authors: Roelof
authors: R
authors: Willemze
authors: GIGA-I3-Hematology, University of Liège, Belgium f.baron@ulg.ac.be.
authors: Frédéric
authors: F
authors: Baron
mesh_terms: D000227:Adenine Nucleotides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000627:therapeutic use*; D000077866:Clofarabine; D003561:Cytarabine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D015870:Gene Expression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D011897:Random Allocation; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D015514:Oncogene Proteins, Fusion; D003561:Cytarabine; D000077866:Clofarabine